Beating Cancer-Related Fatigue With the Untire Mobile App: Protocol for a Waiting List Randomized Controlled Trial.
RCT
app
cancer patients
cancer survivors
fatigue
intervention
mHealth
psycho-oncology
quality of life
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
14 Feb 2020
14 Feb 2020
Historique:
received:
22
08
2019
accepted:
26
11
2019
revised:
20
11
2019
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
5
3
2020
Statut:
epublish
Résumé
Many cancer patients and survivors worldwide experience disabling fatigue as the main side effect of their illness and the treatments involved. Face-to-face therapy is effective in treating cancer-related fatigue (CRF), but it is also resource-intensive. Offering a self-management program via a mobile phone app (ie, the Untire app), based on elements of effective face-to-face treatments, might increase the number of patients receiving adequate support for fatigue and decrease care costs. The aim of this protocol is to describe a randomized controlled trial (RCT) to assess the effectiveness of the Untire app in reducing fatigue in cancer patients and survivors after 12 weeks of app use as compared with a waiting list control group. Substudies nested within this trial include questions concerning the reach and costs of online recruitment and uptake and usage of the Untire app. The Untire app study is a waiting list RCT targeting cancer patients and survivors who experience moderate to severe fatigue via social media (Facebook and Instagram) across 4 English-speaking countries (Australia, Canada, the United Kingdom, and the United States). The Untire app includes psychoeducation and exercises concerning energy conservation, activity management, optimizing restful sleep, mindfulness-based stress reduction, psychosocial support, cognitive behavioral therapy, and physical activity. After randomization, participants in the intervention group could access the Untire app immediately, whereas control participants had no access to the Untire app until the primary follow-up assessment at 12 weeks. Participants completed questionnaires at baseline before randomization and after 4, 8, 12, and 24 weeks. The study outcomes are fatigue (primary) and quality of life (QoL; secondary). Potential moderators and mediators of the hypothesized treatment effect on levels of fatigue and QoL were also assessed. Link clicks and app activation are used to assess reach and uptake, respectively. Log data are used to explore the characteristics of app use. Sample size calculations for the primary outcome showed that we needed to include 164 participants with complete 12-week measures both in the intervention and the control groups. The intention-to-treat approach is used in the primary analyses, which refers to analyzing all participants regardless of their app use. Participants were recruited from March to October 2018. The last participant completed the 24-week assessment in March 2019. This mobile health (mHealth) RCT recruited participants online in multiple countries to examine the uptake and effectiveness of the Untire self-management app to reduce CRF. Many advantages of mHealth apps are assumed, such as the immediate access to the app, the low thresholds to seek support, and the absence of contact with care professionals that will reduce costs. If found effective, this app can easily be offered worldwide to patients experiencing CRF. Netherlands Trial Register NL6642; https://www.trialregister.nl/trial/6642. DERR1-10.2196/15969.
Sections du résumé
BACKGROUND
BACKGROUND
Many cancer patients and survivors worldwide experience disabling fatigue as the main side effect of their illness and the treatments involved. Face-to-face therapy is effective in treating cancer-related fatigue (CRF), but it is also resource-intensive. Offering a self-management program via a mobile phone app (ie, the Untire app), based on elements of effective face-to-face treatments, might increase the number of patients receiving adequate support for fatigue and decrease care costs.
OBJECTIVE
OBJECTIVE
The aim of this protocol is to describe a randomized controlled trial (RCT) to assess the effectiveness of the Untire app in reducing fatigue in cancer patients and survivors after 12 weeks of app use as compared with a waiting list control group. Substudies nested within this trial include questions concerning the reach and costs of online recruitment and uptake and usage of the Untire app.
METHODS
METHODS
The Untire app study is a waiting list RCT targeting cancer patients and survivors who experience moderate to severe fatigue via social media (Facebook and Instagram) across 4 English-speaking countries (Australia, Canada, the United Kingdom, and the United States). The Untire app includes psychoeducation and exercises concerning energy conservation, activity management, optimizing restful sleep, mindfulness-based stress reduction, psychosocial support, cognitive behavioral therapy, and physical activity. After randomization, participants in the intervention group could access the Untire app immediately, whereas control participants had no access to the Untire app until the primary follow-up assessment at 12 weeks. Participants completed questionnaires at baseline before randomization and after 4, 8, 12, and 24 weeks. The study outcomes are fatigue (primary) and quality of life (QoL; secondary). Potential moderators and mediators of the hypothesized treatment effect on levels of fatigue and QoL were also assessed. Link clicks and app activation are used to assess reach and uptake, respectively. Log data are used to explore the characteristics of app use. Sample size calculations for the primary outcome showed that we needed to include 164 participants with complete 12-week measures both in the intervention and the control groups. The intention-to-treat approach is used in the primary analyses, which refers to analyzing all participants regardless of their app use.
RESULTS
RESULTS
Participants were recruited from March to October 2018. The last participant completed the 24-week assessment in March 2019.
CONCLUSIONS
CONCLUSIONS
This mobile health (mHealth) RCT recruited participants online in multiple countries to examine the uptake and effectiveness of the Untire self-management app to reduce CRF. Many advantages of mHealth apps are assumed, such as the immediate access to the app, the low thresholds to seek support, and the absence of contact with care professionals that will reduce costs. If found effective, this app can easily be offered worldwide to patients experiencing CRF.
TRIAL REGISTRATION
BACKGROUND
Netherlands Trial Register NL6642; https://www.trialregister.nl/trial/6642.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/15969.
Identifiants
pubmed: 32130185
pii: v9i2e15969
doi: 10.2196/15969
pmc: PMC7055831
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15969Informations de copyright
©Simon S Spahrkäs, Anne Looijmans, Robbert Sanderman, Mariët Hagedoorn. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 14.02.2020.
Références
Psychooncology. 2012 Mar;21(3):264-72
pubmed: 22383268
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006145
pubmed: 18425939
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Pflege. 2012 Dec;25(6):439-57
pubmed: 23188754
Med Care. 1979 Jul;17(7 Suppl):iii-x, 1-131
pubmed: 459579
Cancer. 2013 Jun 1;119 Suppl 11:2124-30
pubmed: 23695924
Cancer Treat Rev. 2014 Jul;40(6):791-9
pubmed: 24576643
Curr Nutr Rep. 2018 Sep;7(3):59-69
pubmed: 30094747
Exp Ther Med. 2013 Jan;5(1):205-208
pubmed: 23251269
Health Psychol Open. 2018 Oct 08;5(2):2055102918805187
pubmed: 30305916
Ann Intern Med. 2014 Nov 18;161(10 Suppl):S5-12
pubmed: 25402403
J Pain Symptom Manage. 2007 Aug;34(2):126-35
pubmed: 17544246
Qual Life Res. 1998 May;7(4):301-10
pubmed: 9610214
J Pers Soc Psychol. 2003 Apr;84(4):822-48
pubmed: 12703651
Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12
pubmed: 9253778
Qual Life Res. 2000;9(7):847-54
pubmed: 11297027
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Drug Alcohol Depend. 2017 Jan 01;170:37-42
pubmed: 27870987
Int J Behav Med. 2018 Feb;25(1):1-16
pubmed: 28752414
BMJ Innov. 2016 Jan;2(1):14-21
pubmed: 27019745
BMC Med Res Methodol. 2013 Dec 06;13:150
pubmed: 24314204
Ecancermedicalscience. 2018 Mar 20;12:ed81
pubmed: 29662537
Cancer. 2015 Apr 15;121(8):1231-40
pubmed: 25537522
Transl Behav Med. 2013 Dec;3(4):406-15
pubmed: 24294329
Psychopharmacol Bull. 1973 Jan;9(1):13-28
pubmed: 4682398
J Med Internet Res. 2015 Mar 02;17(3):e56
pubmed: 25732936
Br J Cancer. 2008 Nov 4;99(9):1408-14
pubmed: 18941462
J Med Internet Res. 2005 Mar 31;7(1):e11
pubmed: 15829473
J Med Internet Res. 2015 Jan 02;17(1):e1
pubmed: 25565416
Oncologist. 2000;5 Suppl 2:9-12
pubmed: 10896323
Psychooncology. 2018 Mar;27(3):831-837
pubmed: 29076568
J Med Internet Res. 2017 Oct 19;19(10):e336
pubmed: 29051138
Cancer. 2012 Aug 1;118(15):3766-75
pubmed: 22180393
Clin J Oncol Nurs. 2014;18 Suppl:38-58
pubmed: 25427608
Med Care. 2007 May;45(5 Suppl 1):S3-S11
pubmed: 17443116
J Cancer Surviv. 2013 Dec;7(4):602-13
pubmed: 23918453
Psychooncology. 2017 Sep;26(9):1239-1253
pubmed: 28665554
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Med Internet Res. 2009 Apr 03;11(2):e9
pubmed: 19403465
Psychooncology. 2018 Feb;27(2):524-531
pubmed: 28665541